Filings · News reference

Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders

Aug 28, 2026, 9:14 PMBenzinga Newsdesk

-SEC Filing

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 18, 2026, 2:11 PMAvi Kapoor
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
AMLX ANGX DUOL DUOT FOUR
BenzingaAug 5, 2026, 2:20 PMAvi Kapoor
This Civeo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Analysts change outlook on top Wall Street names, including initiations, upgrades, and downgrades. Check our analyst ratings page for details.
CVEO DVLT OBX OLN TKNO
BenzingaAug 5, 2026, 11:21 AMBenzinga Newsdesk
Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma
Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell
OBX